Sodium-glucose cotransporter-2 (SGLT2) inhibitors reduce cardiovascular death or hospitalization for heart failure (HF) and improve quality of life in HF patients through the spectrum of left ventricular ejection fraction (LVEF) and regardless of the presence or absence of type 2 diabetes. They also exhibit cardiorenal benefits in individuals with kidney disease. Therefore, to address the needs of HF clinicians, this symposium will provide case-based learning (after brief summaries of clinical evidence) and commentary by leading HF experts on implications of use of SGLT2 inhibitors in everyday clinical practice.

Faculty:

Stephen Greene, MD 
Mikhail Kosiborod, MD 
Alanna Morris, MD, MSc

Jointly provided by the HFSA and Voxmedia and supported through an independent educational grant from AstraZeneca.